An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Severe Sickle Cell Disease (SCD) and ST-400 in Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant

Condition:   Blood and Lymphatic Diseases Interventions:   Drug: BIVV003;   Drug: ST-400 Sponsor:   Bioverativ, a Sanofi company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials